Dataset Information

V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients.

ABSTRACT:

Background

Anemia is common among end-stage renal disease (ESRD) patients who undergone hemodialysis. The total reduction of red blood cell (RBC) count is associated with poor prognosis in these patients. Although erythropoietin (EPO) has been used as an effective treatment for ESRD patients with anemia, a large number of patients still present poor responses to EPO treatment.

Methods

We measured T-cell receptor sequencing profiles, including length of complementarity-deteremining region 3 (CDR3), intra- and inter-group (EPO resistant vs. responsive) clonotype diversity, V(D)J usage profiles and V-J combinations from ESRD patients and to investigate the correlation between these features and EPO treatment efficacy.

Results

Our results revealed statistical significance in the top 3 ~ 15 most abundant joint distributions of V?/J? among the two groups, suggesting the importance of V or J gene utilization in the EPO response of ESRD patients.

Conclusions

In summary, we provided evidence addressing the potential correlation between the immune repertoire and EPO response in ESRD patients.

Trial registration

TMU-JIRB 201309026. Registered 16 October 2013.

SUBMITTER: Wong HS

PROVIDER: S-EPMC5504791 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients.

Wong Henry Sung-Ching HS Chang Che-Mai CM Kao Chih-Chin CC Hsu Yu-Wen YW Liu Xiao X Chang Wen-Chang WC Wu Mai-Szu MS Chang Wei-Chiao WC

Journal of biomedical science 20170711 1

<h4>Background</h4>Anemia is common among end-stage renal disease (ESRD) patients who undergone hemodialysis. The total reduction of red blood cell (RBC) count is associated with poor prognosis in these patients. Although erythropoietin (EPO) has been used as an effective treatment for ESRD patients with anemia, a large number of patients still present poor responses to EPO treatment.<h4>Methods</h4>We measured T-cell receptor sequencing profiles, including length of complementarity-deteremining ...[more]

PMID: 28697735

Similar Datasets

Project description:OBJECTIVE:Serum albumin is a marker of malnutrition and inflammation and has been demonstrated as a strong predictor of mortality in chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients. Yet, whether serum albumin levels in late-stage CKD are associated with adverse outcomes after the transition to ESRD is unknown. We hypothesize that lower levels and a decline in serum albumin in late-stage CKD are associated with higher risk of mortality and hospitalization rates 1 year after transition to ESRD. DESIGN AND METHODS:This retrospective cohort study included 29,124 US veterans with advanced CKD transitioning to ESRD between 2007 and 2015. We evaluated the association of pre-ESRD (91 days before transition) serum albumin with 12-month post-ESRD all-cause, cardiovascular, and infection-related mortalities and hospitalization rates as well as the association of 1-year pre-ESRD albumin slope and 12-month post-ESRD mortality using hierarchical multivariable adjustments. RESULTS:There was a negative linear association between serum albumin and all-cause mortality, such that risk doubled (hazard ratio [HR]: 2.07, 95% confidence interval [CI]: 1.87, 2.28) for patients with the lowest serum albumin <2.8 g/dL (ref: ?4.0 g/dL) after full adjustment. A consistent relationship was observed between serum albumin and cardiovascular and infection-related mortality, and hospitalization outcomes. An increase in serum albumin of >0.25 g/dL/year was associated with reduced mortality risk (HR: 0.76, 95% CI: 0.63, 0.91) compared with a slight decline in albumin (ref: >-0.25 to 0 g/dL/year), whereas a decline more than 0.5 g/dL/year was associated with a 55% higher risk in mortality (HR: 1.55, 95% CI: 1.43, 1.68) in fully adjusted models. CONCLUSIONS:Lower pre-ESRD serum albumin was associated with higher post-ESRD all-cause, cardiovascular, and infection-related mortalities and hospitalization rates. Declining serum albumin levels in the pre-ESRD period were also associated with worse 12-month post-ESRD mortality.

Dataset Information

V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients.

Background

Methods

Results

Conclusions

Trial registration

Publications

V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets